Specifically, olaparib was approved by the FDA in March 2022 as adjuvant therapy for high-risk HER2 negative breast cancer with germline BRCA1/2 mutations based on the OlympiA trial, which demonstrated improvement in DFS (85.9% vs. 77.1%, HR 0.68; 95% CI 0.50 to 0.91; p = 0.0091) and OS (HR 0.68; 98.5% CI 0.47 to 0.97; p = 0.009) [57,67]. This evidence concerns the gene BRCA1 and breast carcinoma.